Article

Detection of residual disease after neoadjuvant therapy in breast cancer using personalized circulating tumor DNA analysis

2018-09-26

Abstract excerpt

Accurate detection of minimal residual disease (MRD) can guide individualized management of early stage cancer patients, but current diagnostic approaches lack adequate sensitivity. Circulating tumor DNA (ctDNA) analysis has shown promise for recurrence monitoring but MRD detection immediately after neoadjuvant therapy or surgical resection has remained challenging. We have developed TARgeted DIgital Sequencing (T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2d9e737a-756b-567a-ab99-451a5b1df26b
DOI: 10.1101/425470

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Detection of residual disease after neoadjuvant therapy in breast cancer using personalized circulating tumor DNA analysisDOI 10.1101/425470Read

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read

Revolutionizing Detection of Minimal Residual Disease in Breast Cancer Using Patient-Derived Gene SignatureSemantic proximity Read

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast CancerSemantic proximity Read

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapySemantic proximity Read

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030Semantic proximity Read

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read

Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast CancerSemantic proximity Read

Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancerSemantic proximity Read

Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNASemantic proximity Read

Whole genome sequencing-powered ctDNA sequencing for breast cancer detectionSemantic proximity Read

Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance.Semantic proximity Read

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assaySemantic proximity Read